Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas
NCT03631953Phase 1Active, not recruiting
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Start
- Sep 2019
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of alpelisib and trametinib in meningioma, sponsored by Assistance Publique-Hôpitaux de Marseille. Primary endpoint: Dose Limiting Toxicity at 36 months. Started Sep 2019; status: active, not recruiting.
02
Drugs
alpelisibtrametinib
03
Conditions
meningioma
Beyond the preview
Go deeper on NCT03631953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03631953.